Table 1.

SDT-based combination therapy.

Sonosensitizer	Treatment Modalities	US Parameters	Target	Ref.
Au NPL@TiO2	SDT + PTT	3.0 MHz 0.5 W/cm2	HeLa cells	[127]
Ir-B-TiO2@CCM	SDT + PTT	1.0 MHz 1 Wcm2	HeLa cells	[128]
ZrO2−x@PEG	SDT + PTT	1.0 MHz 0.5 W/cm2	4T1 cells	[129]
Porous carbon nanospheres	SDT + PTT	1.0 MHz 1 W/cm2	4T1 cells	[130]
Au-MnO Nanoparticles	SDT + CDT	1.0 MHz 2 W/cm2	MCF-7cells	[131]
CoFe2O4	SDT + CDT	1.0 MHz 1 W/cm2	4T1 cells	[132]
Fe-TiO2 nanodots	SDT + CDT	40 kHz 3 W/cm2	4T1 cells	[133]
AIPH@Cu-MOF	SDT + CDT	1.0 MHz 0.5 W/cm2	Panc02-Luc cells	[134]
Au-PTX NPs	SDT + chemotherapy	1.0 MHz 1 W/cm2	C540 cells	[135]
Dox@FeCPs	SDT + chemotherapy	1.0 MHz 1.75 W/cm2	CT26 cells	[136]
TiO2: Gd@DOX/FA	SDT + chemotherapy	3.3 MHz 1 W/cm2	LNCaP cells	[137]
TiO2-Ce6-CpG	SDT + immunotherapy	1.0 MHz 1 W/cm2	Hepa1-6	[138]
(TPP)/R837@M	SDT + immunotherapy	3.0 MHz 1.5 W/cm2	4T1 cells	[139]